{"id":"W3211568627","doi":"10.1182/blood-2021-146570","title":"Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Fludarabine; Progression-free survival; Neutropenia; Oncology; Ibrutinib; Toxicity; Chemotherapy; Leukemia; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009810036,0.0004546497,0.001345261,0.0002382633,0.0001311501,0.00004403304,0.0006769461,0.0004996049,0.001073992],"category_scores_gemma":[0.003059707,0.0003203614,0.0004778969,0.001577998,0.0003909439,0.0001167841,0.0006137922,0.0009472474,0.0001474303],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.05113711,"about_ca_system_score_gemma":0.1294102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002312965,"about_ca_topic_score_gemma":0.003551876,"domain_scores_codex":[0.9950754,0.000265638,0.001228554,0.0008838694,0.001500995,0.001045551],"domain_scores_gemma":[0.9962826,0.0007731668,0.0003329439,0.001937943,0.0003587514,0.0003146312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.644492,0.02717697,0.01070722,0.02310684,0.01032458,0.03950899,0.01076912,0.003301082,0.1176643,0.008174362,0.07317964,0.03159483],"study_design_scores_gemma":[0.9454523,0.001557088,0.001648214,0.001440117,0.0007891716,0.001008385,0.0002802179,0.006604978,0.03452808,0.000159314,0.006081718,0.00045044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917097,0.003163396,0.00001777764,0.0003593944,0.0008943349,0.00157792,0.00004820216,0.0001005188,0.002128734],"genre_scores_gemma":[0.9925929,0.0004307389,0.0003396793,0.00024247,0.000760708,0.0001113167,0.000047317,0.0001256792,0.005349137],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3009602,"threshold_uncertainty_score":0.9999248,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03271177986919534,"score_gpt":0.3020224346088241,"score_spread":0.2693106547396288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}